Aims Non-renal extravasation of phosphate from the circulation and transient accumulation into tissues and extracellular fluid is a regulated process of acute phosphate homeostasis that is not well understood. This process is especially relevant in the setting of chronic kidney disease (CKD), where exposure to increased phosphate is prolonged due to inefficient kidney excretion. Furthermore, CKD-associated mineral dysregulation induces pathological accumulation of phosphate causing vascular calcification (VC). Our objective was to determine whether the systemic response to acute phosphate challenges is altered by VC. Methods/Results After bolus phosphate administration, circulating and tissue deposition of this challenge was assessed in two rat models of VC using a radiolabelled phosphate tracer. In an adenine-induced model of CKD (N = 70), animals with VC had a blunted elevation of circulating 33PO4 following oral phosphate administration (p < 0.01), and the discordant deposition could be traced to the calcified arteries (11.4[7.5,13.1]vs.43.0[35.5, 53.7] pmol/ng tissue, p < 0.001). In a non-CKD model of VC, calcification was induced with 0.5ug/kg calcitriol and then withdrawn (N = 24). New phosphate uptake by the calcified vasculature correlated to the pre-existing burden of calcification (r = 38, p < 0.001) and was substantially attenuated in the absence of calcification stimulus (p < 0.01). Phosphate accrual was stimulated by the phosphate challenge, and not present to the same degree during passive disposition of circulating phosphate. Further, the form of phosphate that deposited to the vasculature was predominately amorphous inorganic phosphate, and not that which was bound in matured calciprotein particles. Conclusions In the process of calcification, arteries acutely deposit substantial amorphous phosphate while blunting the elevation in the circulation, thereby altering the systemic disposition of phosphate, and identifying VC as a participatory mineral homeostatic organ. This study demonstrates the negative vascular consequence of acute fluctuations in circulating phosphate, and supports the importance of phosphate bioavailability and diet management in CKD patients as a mediator of cardiovascular risk.
BackgroundNon-renal extravasation of phosphate from the circulation and transient accumulation into tissues and extracellular fluid is a regulated process of acute phosphate homeostasis that is not well understood. Following oral consumption of phosphate, circulating levels normalize long before urinary excretion has been completed. This process is particularly critical in the setting of chronic kidney disease (CKD), where phosphate exposure is prolonged due to inefficient kidney excretion. Furthermore, CKD-associated dysregulation of mineral metabolism exacerbates pathological accumulation of phosphate causing vascular calcification (VC). In the present study, the objective was to determine whether the processes involved in the development and progression of VC are also normally involved in the systemic acute response to oral phosphate.MethodsAcute circulating and physiological phosphate movement and tissue deposition was assessed in two experimental rat models of VC using radio-labelled phosphate challenge. In an adenine-induced model of CKD, VC was induced with high dietary phosphate. Animals were euthanized 2 and 6 hours after oral consumption of radiolabelled phosphate. A non-CKD model of VC was induced with 0.5ug/kg calcitriol and then withdrawn, and radiolabelled phosphate was then given to assess for vascular preference for phosphate uptake with and without the presence of an active calcification stimulus. Samples of 50 different tissues were collected to assess tissue accumulation of de novo phosphate in response the challenges.ResultsAnimals with CKD and VC have a blunted elevation of circulating 33PO4 following oral phosphate administration and the discordant deposition can be traced to the calcifying vasculature. Deposition of de novo phosphate is present until at least 6 hours, which after active gut absorption. The accrual is stimulated by a phosphate challenge, and not present in the same degree during passive disposition of circulating phosphate. The extent of new transport to the calcifying vasculature correlates to the pre-existing burden of calcification, and can be substantially attenuated by removing the stimulus for calcification.ConclusionsOur data indicate that calcifying arteries alter the systemic disposition of a phosphate challenge and acutely deposit substantial phosphate. This study supports the importance of diet as it relates to acute fluctuations of circulating phosphate and the importance of bioavailability and meal-to-meal management in CKD patients as a mediator of cardiovascular risk.
Mineral bone disorder and vascular calcification (VC) are substantial contributors to the elevated cardiovascular disease (CVD) burden in chronic kidney disease patients. The degree to which the uremic milieu and mineral dysregulation individually contribute to this CVD is poorly understood. Calcitriol, the active form of vitamin D, is a key regulator of mineral metabolism. In this study, we present a model of rapid calcitriol‐induced VC in rats with normal kidney function, with findings that point to active and non‐active processes of calcification being fundamentally different phenotypes.Male Sprague Dawley rats (n=17, 15 weeks) were injected with 0.5 μg/kg/day calcitriol SQ for 8 days. On the 9th day, half of the animals were sacrificed (n=8, CxE), and the remainder were sacrificed 14 days after the cessation of calcitriol (n=9, CxL). Control animals (n=6) followed the same protocol. Circulating calcium, phosphate, and hormones regulating mineral metabolism (parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF‐23)) were measured every two days. At sacrifice, animals underwent an IV infusion of 300μmol PO4 spiked with radioactive 33PO4. Forty body tissues, including 14 across the vascular tree, were harvested and analyzed for mineral content/VC (calcium and phosphate) as well as acute phosphate deposition (33PO4 accrual).Daily administration of high‐dose calcitriol significantly elevated FGF‐23 and calcium, and suppressed PTH after only 2 doses, however, 14 days after calcitriol withdrawal, the analytes had fully normalized (Figure 1). Substantial VC was generated over the 8 days of treatment (7.8±4.2 v. 166±142 nmol Ca/mg tissue, p<0.001) and persisted 14 days after stopping treatment (540±492 nmol Ca/mg tissue). Following IV infusion of phosphate labelled with 33PO4, animals sacrificed directly following calcitriol treatment (CxE) had greater accrual of phosphate acutely in the vascular bed compared to those sacrificed 14 days after the cessation of treatment (CxL; −50.4%, p<0.001), despite having sustained levels of resident VC (Figure 2).Despite the similar magnitude of VC, acute deposition of phosphate following the IV load, a potential measure of calcification activity, was significantly greater during calcitriol treatment (CxE) than after stopping it (CxL). This suggests that the VC itself does not mediate the increased accrual of phosphate, but rather the cellular phenotype of the tissue. Also, it was this acute activity, not the resident VC, that aligned with dysregulated mineral metabolism markers. The transcriptional, cellular, and physiological differences of these two states, as well as their differential associations with circulating analytes are not currently differentiated in VC research. These differences likely have an important role in VC present in humans.Support or Funding InformationThis research was funded by Canadian Institutes of Health Research and Vanier Canada Graduate Scholarships.This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.
BackgroundChronic kidney disease (CKD) patients have impaired phosphate and calcium excretion as well as vitamin D deficiency, which exacerbates secondary hyperparathyroidism (SHPT). A decrease in renal CYP27B1 conversion of calcifediol leads to reduced levels of calcitriol. SHPT leads to increased bone resorption and is a risk factor for vascular calcification and cardiovascular disease in the CKD population. The effectiveness of calcitriol in managing SHPT is problematic, as significant resistance develops with chronic therapy; a condition that can lead to parathyroidectomy.AimDetermine the time course and impact of increasing dietary phosphate on calcitriol‐induced suppression of PTH in experimental CKD.MethodsIn Sprague Dawley rats (N=10), a 0.25% adenine 0.5% phosphate diet was fed for 4–5 weeks to generate stable CKD. A single oral calcitriol dose (160ng/kg) was given pre‐CKD, and at 1, 3, and 5 (off adenine) weeks of CKD induction (0.5% dietary phosphate). From 7–8 weeks rats were given increased dietary phosphate (1.0%) and the response to calcitriol was re‐assessed. Changes in circulating PTH, fibroblast growth factor 23 (FGF‐23), calcium and phosphate in response to the biweekly sham or calcitriol dosing were assessed at 0, 4, 8 and 24 hours.ResultsIn CKD rats, PTH increased from 80±25.8 pg/mL to 221±66.7 pg/mL (week 5) and FGF‐23 from 421±26.0 pg/mL to 6803±1510.2 pg/mL (week 5). The two week 1% phosphate markedly increased PTH to 1342±310 pg/mL (8 weeks) and FGF‐23 to 14490±4980.8 pg/mL (7 weeks). In CKD rats on a low phosphate diet, the biweekly calcitriol dose reduced PTH by up to 44% and raised FGF‐23 by 82% whereas in rats on high dietary phosphate PTH was no longer responsive to calcitriol suppression.ConclusionResponses to calcitriol therapy were attenuated with increasing dietary phosphate and increasing CKD severity. This study supports the importance of dietary phosphate restriction in the CKD population to limit the impact of PTH responsiveness and mineral bone disease in this population.SignificanceCharacterization of calcitriol resistance will help to develop new dosing strategies for vitamin D receptor agonists in this population and prevent SHPT and parathyroidectomies.Support or Funding InformationFunded by the Canadian Institutes of Health ResearchThis abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.